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Abstract
Angiogenesis is a critical step during cancer progression. The vascular endothelial growth factor
(VEGF) is a major stimulator for angiogenesis and is predominantly contributed by cancer cells in
tumors. Inhibition of the VEGF signaling pathway has shown promising therapeutic benefits for
cancer patients, but adaptive tumor responses are often observed, indicating the need for further
understanding of VEGF regulation. We report that a novel G protein-coupled receptor, GPR56,
inhibits VEGF production from the melanoma cell lines and impedes melanoma angiogenesis and
growth, through the serine threonine proline-rich (STP) segment in its N-terminus and a signaling
pathway involving protein kinase Cα. We also present evidence that the two fragments of GPR56,
which are generated by autocatalyzed cleavage, played distinct roles in regulating VEGF
production and melanoma progression. Finally, consistent with its suppressive roles in melanoma
progression, the expression levels of GPR56 are inversely correlated with the malignancy of
melanomas in human subjects. We propose that components of the GPR56-mediated signal
pathway may serve as new targets for anti-angiogenic treatment of melanoma.
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Introduction
Angiogenesis is a process of nascent blood vessel formation (1) and is critical for tumor
growth and metastasis (2). When tumors reach ~1 mm in diameter, hypoxia develops and
induces the secretion of vascular growth factor A (VEGFA, or VEGF) from cancer cells (3).
VEGF recruits endothelial cells and stimulates new blood vessel formation (4) to ensure
sufficient oxygen and nutrient supply for the proliferation of cancer cells. Inhibiting this
process reduces tumor sizes and has been proposed as a non-conventional therapy for cancer
Correspondence: Lei Xu, Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642,
lei_xu@urmc.rochester.edu.
*Current address: Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642.
Conflicts of Interest: the authors declare no conflict of interest.
NIH Public Access
Author Manuscript
Cancer Res. Author manuscript; available in PMC 2012 February 15.
Published in final edited form as:
Cancer Res. 2011 August 15; 71(16): 5558–5568. doi:10.1158/0008-5472.CAN-10-4543.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
treatment (5, 6). Various angiogenesis inhibitors have been developed and many of them
show promising tumor inhibitory effects (7). However, adaptive responses to single anti-
angiogenic therapy, manifested as increased invasion and metastasis of cancer cells, have
been observed both experimentally and clinically (8–10). The mechanisms for this adaptive
response are not clear, but its occurrence strongly argues for combinations of anti-
angiogenic regimens to effectively treat cancer.
VEGF is a potent growth factor for angiogenesis and is a common target for anti-
angiogenesis inhibition (11). It binds to the VEGF receptors (VEGFRs) on endothelial cells
and promotes their proliferation and migration during angiogenesis. The main source of
VEGF in tumors is cancer cells and its expression is tightly regulated at both transcriptional
and posttranscriptional levels (12). Under hypoxic conditions, VEGF mRNA is induced by
the hypoxia-inducible factor alpha (HIF-1alpha) and subsequently regulated by alternative
splicing. Four main isoforms of VEGF have been identified: VEGF121, VEGF165, VEGF189,
and VEGF206, with VEGF165 being the most abundantly expressed. All VEGF isoforms
except VEGF121 could associate with extracellular matrix (ECM). The ECM-bound VEGF
can be released and activated by heparinases or matrix metalloproteinases, providing an
additional layer of regulation for VEGF activity in vivo (13). A less well-characterized
mechanism of VEGF regulation is secretion. VEGF contains a signal peptide (14) and
presumably is secreted through conventional vesicle trafficking process, from ER to Golgi,
and to plasma membrane. In mast cells (15) and neutrophils (16), for example, VEGF is
stored in secretory granules, and its release is stimulated by the activation of protein kinase
C (PKC).
We report here that VEGF production from melanoma cells is regulated by an atypical G
protein-coupled receptor (GPCR), GPR56. GPR56 belongs to the family of adhesion
GPCRs, a newly identified family of class B GPCRs implicated in both cell adhesion and G
protein-coupled signaling (17). The adhesion GPCRs are highly conserved and their
importance in development and diseases has been increasingly recognized (17–22), but their
regulatory mechanisms remain poorly understood. Adhesion GPCRs share a GPCR
proteolytic site (GPS), through which the extracellular stalks are separated from the
transmembrane domains by autocatalytic cleavage. The cleaved fragments could still
associate with each other non-covalently and form a heterodimeric complex. This cleavage
in adhesion GPCRs is required for their proper functions, since mutations in GPS motifs
resulted in failure of the receptors to localize on cell surface (23, 24).
Our previous work showed that GPR56 inhibited melanoma growth and metastasis from
MC-1 cells in a xenograft model (25). We present evidence here that, depending on the
presence or absence of a serine threonine proline-rich (STP) segment in its N-terminus,
GPR56 differentially regulates VEGF production, angiogenesis, and melanoma growth, via
a signaling pathway involving PKCα. We propose that GPR56 exists in different activation
states in melanoma cells, which are modulated by its STP segment and induce opposing
outcomes on angiogenesis and melanoma progression. Specific targeting of tumor-
promoting activity of GPR56 may thus serve as a new strategy for angiogenesis inhibition
and melanoma treatment.
Materials and Methods
Cell lines
The MC-1, SM, and MA-1 cells were derived from the human melanoma cell line, A375
(ATCC #CRL-1619) (25, 26), and maintained in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% FBS and 4 mM glutamine. WM266-4 cells were obtained from ATCC
(CRL-1676) and maintained in Minimal Essential Medium with Earle’s salt, 10% FBS, 0.1
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mM non-essential amino acids, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, and 2
mM glutamine. YURIF cells were purchased from the Yale University Cell Core Facility
(27) and maintained in Opi-MEM (Invitrogen) with 5% FBS. HEK293 cells were
maintained in DMEM with 10% FBS and 2 mM glutamine. All the cell lines were passaged
in our laboratory for less than six months after receipt.
Mice
NOD-SCID mice (NOD.CB17-Prkdcscid/J) and NSG mice (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) were purchased from the Jackson Laboratory (Bar Harbor, Maine).
Gpr56−/− mice (Genentech Inc., CA) were maintained through crossbreedings between
Gpr56+/− mice. All the mice were housed in the animal facility at the University of
Rochester Medical Center or Massachusetts Institute of Technology, in accordance to the
animal care guidelines from the Division of Laboratory Animal Medicine at University of
Rochester Medical Center or MIT.
ELISA for VEGF Quantification
Cells were seeded at a density of 1.0 × 105 cells per well in 24-well plates and cultured in
serum-free medium for three days. Media were collected every 24 hours for VEGF-specific
ELISA analyses, following the instructions from the manufacturer (R&D Systems).
To test the effects of PKC on VEGF production, MC-1 cells were incubated with the PKC
inhibitors, chelerythrine chloride and Ro-31-8425 (EMD4Biosciences, NJ), or the PKC
activator, phorbol myristate acetate (PMA; Sigma, MO), for 48 hours in serum-free medium.
The media of the treated cells were subjected to ELISA. To examine the effects of PKCα on
VEGF production, MC-1(ΔSTP-GPR56) and MC-1(GPRC) cells were transiently
transfected with the construct expressing a dominant negative (DN) mutant of PKCα, or
vector control (Addgene). Media were collected 48 hours after transfection for ELISA
analyses. To assess whether the DN- PKCα sequesters PMA-induced VEGF production,
MC-1(GPR56) cells transiently expressing DN-PKCα or vector control were subjected to
PMA (10 µg/ml) stimulation. Media were collected 48 hours after stimulation for ELISA
analyses,
Analyses of Activation of PKC Isoforms
Cell fractionation to assess activated PKC isoforms was performed as previously reported
(28). Briefly, cells were lysed in isotonic buffer (20 mM Tris–HCl (pH 7.5, 150 mM NaCl,
10 mM EDTA, 5 mM EGTA, 20 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM
sodium vanadate, 1 µM okadaic acid and a cocktail of protease inhibitor). Membrane
fractions were collected after two rounds of centrifugations and were subjected to western
blot analyses, using antibodies against PKCα, PKCβ1, PKCβ2, PKCγ, PKCδ, or PKCµ (1:
1000, Santa Cruz Biotechnology). The rabbit anti-LRP6 antibody (1: 500, Cell Signaling)
was used as a loading control. The intensity of each PKC band was measured by
AlphaImager software and normalized to the intensity of LRP6 band from the same sample.
The ratio of the PKC level in MC-1(GPR56), MC-1(ΔSTP-GPR56), or MC-1(GPRC) cells,
over that in MC-1(EV) cells (which was arbitrarily set to 1) was defined as the “Relative
Intensity” score.
Western Blots
Cells were lysed in RIPA buffer and separated on a 12% SDS-polyacrylamide gel for
western blot analyses using the goat anti-VEGF antibody (0.2 mg/ml, R&D systems, MN),
sheep anti-GPRN (0.4 mg/ml, R&D systems), rabbit anti-GPRC (1– 300), FcGPRN (1 mg/
ml), mouse anti-TG2 (1: 100, Abcam, MA), or mouse anti-GAPDH (1: 1000) antibodies,
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followed by detection by HRP-conjugated secondary antibodies and enhanced
chemiluminescence detection system (Pelkin Elmer, MA).
Tumor Studies
5 × 105 of melanoma cells were injected subcutaneously into NOD-SCID, or NSG mice.
Tumor were harvested and weighted five weeks after injections. To study tumor
angiogenesis, frozen sections of tumors were stained with rat anti-PECAM antibody (1:5,
BD Pharmingen, CA), or mouse anti-human vimentin antibody (1:50, Leica Microsystems,
IL), and rabbit anti-GPRC antibody (1: 300), followed by detection with Alexa 488 or Alexa
594 donkey anti-rabbit, anti-mouse, or anti-rat secondary antibodies (1: 400, Invitrogen).
Images were captured by the SPOT software and processed with Adobe Photoshop. The
numbers of blood vessels in two to five randomly chosen fields on each tumor section, or
GPR56-positive and GPR56-negative areas on each GPR56-expressing tumor section, were
counted.
Results
GPR56 inhibits angiogenesis in melanoma
We previously reported that GPR56 inhibited melanoma growth and metastasis in xenograft
models (25). Angiogenesis is a critical process during tumor progression (2). To determine
whether GPR56 inhibits melanoma progression by regulating angiogenesis, tumor sections
from MC-1 cells expressing GPR56 or vector control were sectioned and stained with an
antibody against the platelet and endothelial cell adhesion molecule-1 (PECAM-1).
Significantly fewer blood vessels were observed on sections from MC-1(GPR) cells than the
controls (Figure 1A and B), suggesting that GPR56 inhibits angiogenesis in melanomas.
We frequently observed loss of GPR56 expression in some areas of tumors from
MC-1(GPR) cells, probably due to the growth advantage of cells that express low levels of
ectopic GPR56. We postulated that these areas would contain more blood vessels than the
adjacent areas that retain GPR56 expression. To test this, MC-1(GPR56) tumor sections
were co-stained with the anti-GPR56 antibody (anti-GPRC) and the anti-PECAM antibody,
or an antibody against the human-specific vimentin (Figure 1A and Supplementary Figure
S1). GPR56-low and–high areas that contain tumor cells but not mouse stroma were
selected. Quantification of blood vessels in these areas revealed an inverse relationship
between expression levels of GPR56 and blood vessel density (Figure 1A and C), arguing
strongly that ectopic expression of GPR56 in MC-1 cells inhibits melanoma angiogenesis.
Expression of the C-terminal fragment of GPR56 induces angiogenesis and melanoma
growth
Like many members of the adhesion GPCR family, mature GPR56 receptor is cleaved into
two fragments at the junction between its N-terminus (GPRN) and C-terminal
transmembrane domains (GPRC) (25). The GPRN and GPRC fragments still associate with
each other after cleavage, but significant portions of them remain unbound. We
hypothesized that the GPRN signals through GPRC to inhibit melanoma growth and
angiogenesis and deletion of GPRN in GPR56 should abolish this inhibition. To test this, the
GPRC fragment was over-expressed in MC-1 cells. This expression did not alter cell
proliferation significantly in vitro (Supplementary Figure S2), but, in vivo, it not only failed
to inhibit melanoma growth, but dramatically induced melanoma growth and angiogenesis
(Figure 2A–C), in direct contrast with the inhibition observed from full-length GPR56.
These results indicated a potential antagonistic relationship between the GPRN and GPRC
fragments in MC-1 cells.
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The STP segment in GPR56 binds to TG2 and its deletion in GPR56 led to enhanced
angiogenesis and tumor growth
The antagonistic relationship of GPRN and GPRC fragments implicated from the above
finding led us to speculate that a factor might bind to GPRN and modulate the stimulatory or
inhibitory effects of GPRC. We previously reported that tissue transglutaminse, TG2, binds
to GPRN (25). To test whether TG2 might mediate the inhibitory function of GPRC, we
mapped the region in GPR56 that binds to TG2. GPRN fragments of various lengths were
expressed and purified as human Fc fusion proteins (Supplementary Figure S3A and B) and
their binding to TG2 was tested on overlay assays (25). A serine, threonine, proline-rich
(STP) segment of around 70 aa was shown to be both necessary and sufficient for binding
with TG2 (Supplementary Figure S3C and D).
We reasoned that, if TG2 mediates the suppressive roles of GPR56 in melanoma
progression, deletion of the STP motif in GPR56 would reverse the inhibition by GPR56. To
test this hypothesis, ΔSTP-GPR56 was expressed in MC-1 cells (MC-1(ΔSTP-GPR56)),
processed into a C-terminal fragment of ~25 kDa and an N-terminal fragment of ~45 kDa
(Figure 3A), and localized on cell surface as the full-length GPR56 (Supplementary Figure
S4). The expression of ΔSTP-GPR56 did not perturb MC-1 cell proliferation significantly in
vitro (Supplementary Figure S2), but led to increased tumor growth and blood vessel
densities in vivo (Figure 3B, C and D), similar to GPRC but in contrast to the full-length
receptor, indicating that the STP segment is required for the inhibitory effect of GPR56 on
melanoma angiogenesis and growth.
ΔSTP-GPR56 induces VEGF production in melanoma cell lines
To examine whether GPR56 affects tumor angiogenesis by modulating VEGF production,
the concentrations of VEGF in the media from the MC-1(EV), MC-1(GPR), and
MC-1(ΔSTP-GPR56) cells were determined by ELISA. VEGF was lower in the media of
MC-1(GPR) cells than that of MC-1(EV) cells (Figure 4A), but dramatically elevated in the
media from MC-1 (ΔSTP-GPR56) and MC-1(GPRC) cells (Figure 4A and B), suggesting
that GPR56 inhibits, but ΔSTP-GPR56 or GPRC promotes, the production of VEGF by
MC-1 cells. Consistent with these in vitro observations, the level of VEGF in the circulation
of mice bearing MC-1(ΔSTP-GPR56) cells or MC-1(GPRC) tumors was higher than
controls, and the reverse was observed for MC-1(GPR56) tumors (Supplementary Figure
S5). To examine whether GPR56 regulates VEGF production in melanoma cells other than
MC-1 cells, ΔSTP-GPR56 was expressed in four additional human melanoma cell lines,
SM, WM266-4, MA-1, and YURIF. Its expression induced VEGF production in all of them
(Figure 4C), suggesting that regulation of VEGF production by GPR56 might be a shared
mechanism in malignant melanoma.
The above opposing roles of GPRC and full-length GPR56 on VEGF production predicted
an antagonistic relationship between GPRN and GPRC in melanoma cells. To directly test
this, purified FcGPRN fusion protein (shown as FcGPRN-1 in Figure S3) was added onto
MC-1(GPRC) cells and resulted in a significant reduction of VEGF production relative to
controls (Figure 4D), suggesting strongly that GPRN inhibits the activity of GPRC during
VEGF production of melanoma cells. Since GPRC could be detected in both “GPRN-
bound” and “GPRN-free” states in melanoma cell lysates (25), depleting the whole GPR56
molecule would abolish both and, depending on the ratio of the two states, may result in no
net change or cell-specific changes of VEGF production in melanoma cells. Consistent with
this, we did not observe significant changes of VEGF production from MA-1 cells
expressing GPR56 shRNAs (Supplementary Figure S6).
Yang et al. Page 5
Cancer Res. Author manuscript; available in PMC 2012 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The level of VEGF produced from MC-1(ΔSTP-GPR56) cells was increased relative to
controls, demonstrating that the STP segment in GPR56 is essential for its inhibitory role on
VEGF production. The STP segment binds to TG2, therefore TG2 might participate in the
inhibition of VEGF production by GPR56. To test this, TG2 mRNA was knocked down in
MC-1 cells by shRNAs (Supplementary Figure S7A). Although a minimal increase of
VEGF was observed in the MC-1(TG2-shRNA) cells relative to the controls (Supplementary
Figure S7B), this increase was much smaller than the massive induction of VEGF observed
in MC-1(ΔSTP-GPR56) cells, indicating that TG2 might not mediate the inhibitory effects
of GPR56 on VEGF production.
We next explored the molecular mechanism by which GPR56 might regulate VEGF
production in MC-1 cells. We did not observe significant difference in VEGF mRNA levels
among the MC-1(EV), MC-1(GPR), and MC-1(GPRC) cells; the level of VEGF mRNA in
MC-1(ΔSTP-GPR56) cells was slightly higher than those in the other two cell lines, but the
magnitude of increase (~2 fold) could not account for the large increase of VEGF levels in
the conditioned medium (> 20 fold) (Supplementary Figure S8A). Similarly, no significant
difference in intracellular VEGF levels was observed between the MC-1(EV) and
MC-1(GPR) cells, and in MC-1(ΔSTP-GPR56) cells, the amount of intracellular VEGF was
reduced relative to the other two cell lines (Supplementary Figure S8B). We also did not
observe alterations in alternative splicing or ECM retention of VEGF in MC-1 cells
expressing GPR56 or ΔSTP-GPR56 (data not shown). These data collectively imply that
GPR56 might not regulate VEGF production at the levels of mRNA or protein synthesis, but
instead might inhibit its secretion/release from melanoma cells.
VEGF Secreted from MC-1(EV), MC-1(GPR56), and MC-1(ΔSTP-GPR56) cells contribute to
angiogenesis and tumor growth
VEGF is a major stimulator of angiogenesis during development and diseases. In tumors, it
is mainly secreted by cancer cells (30) and its level correlates with poor prognosis of cancer
(31). To test whether VEGF secreted from MC-1 cells contribute to the angiogenesis and
tumor progression regulated by GPR56, VEGF mRNA was knocked down in MC-1(ΔSTP-
GPR56) cells by shRNAs (Figure 4E). These MC-1(ΔSTP-GPR56+VEGF-shRNA) cells
were injected subcutaneously into mice. Tumor growth from these cells was significantly
impaired compared with controls (Figure 4F), demonstrating that VEGF produced from
MC-1(ΔSTP-GPR56) cells directly contributes to their tumor progression. Consistent with
this, conditioned media from MC-1(ΔSTP-GPR56) cells accelerated the wound closure of
endothelial monolayer in a VEGF-dependent manner in scratch assays (Supplementary
Figure S9A and B).
GPR56 regulates VEGF production through protein kinase Cα (PKCα)
PKC activation has been shown to induce VEGF release from specific granules in multiple
cell types (16, 32, 33). To test whether GPR56 also regulates VEGF secretion in melanoma
cells through PKC, phorbol myristate acetate (PMA), a potent PKC activator, was added to
MC-1(GPR) cells and shown to abrogate the inhibition of VEGF secretion by GPR56
(Figure 5A). Conversely, administration of PKC inhibitors, chelerythrine chloride and
Ro-31-8425, resulted in significant reduction of VEGF secretion in MC-1 and MC-1(ΔSTP-
GPR56) cells (Figure 5B and C), suggesting that GPR56 regulates VEGF production from
MC-1 cells via PKC.
PKCs are represented by as many as ten different isoforms (34). Except for the two atypical
PKCs, all other eight isoforms (PKCα, PKCβ1, PKCβ2, PKCγ, PKCδ, PKCε, PKCη, PKCθ)
are sensitive to PMA activation and could be involved in stimulating VEGF secretion. To
examine which isoform might be regulated by GPR56, we investigated their activities in
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MC-1 cells expressing full-length GPR56, ΔSTP-GPR56, GPRC, and vector control.
Because activated PKC typically translocates from cytosol to membranes (35), its level in
the particular fraction of cell lysates directly correlates with its activation state.
Consequently, the particular fractions of MC-1(EV), MC-1(GPR), MC-1(ΔSTP-GPR), and
MC-1(GPRC) cells were collected and the levels of PKCα, PKCβ1, PKCβ2, PKCγ, PKCε,
and PKCε in each fraction were determined by western blotting analyses using isoform-
specific antibodies. We found that the level of PKCα was reduced in the particular fractions
of MC-1(GPR) cells and increased in those of MC-1(ΔSTP-GPR) and MC-1(GPRC) cells
(Figure 5D and Supplementary Figure S10), suggesting that PKCα is inhibited by full-length
GPR56 and activated by ΔSTP-GPR56 and GPRC, and thus may mediate the regulation of
VEGF production by these receptors. Consistent with this, expression of a dominant
negative mutant of PKCα led to a significant reduction of VEGF secretion in MC-1(ΔSTP-
GPR) and MC-1(GPRC) cells as well as the PMA-induced VEGF secretion from
MC-1(GPR56) cells (Figure 5E and F). The level of PKCβ2 was decreased in the particular
fractions of MC-1(GPR) cells, but did not show any increase in those of MC-1(ΔSTP-GPR)
and MC-1(GPRC) cells, thus unlikely contribute directly to the VEGF production regulated
by GPR56 and its derivatives. None of the remaining PKC isoforms tested showed
significant differential regulation by GPR56 (Figure 5D and Supplementary Figure S10).
Expression levels of GPR56 are inversely correlated with the progression of human
melanomas
To investigate expression of GPR56 in melanocytic lesions, we analyzed the expression
pattern of GPR56 on human tissue microarrays (TMAs) of nevi, primary melanomas, and
metastatic melanomas by immunohistochemistry using an antibody raised against the STP
segment of GPR56. The antibody specifically recognized GPR56 on formalin-fixed sections
from mouse tissues and human melanoma xenografts (Figure 6A and B). Expression
intensities of GPR56 on the TMAs were determined by one of us (G.S.) and decreased
significantly as melanoma progresses from nevi to primary melanomas, and appeared to
follow this trend of decline (although not with statistical significance) in metastatic
melanomas (Figure 6C and D).
Discussion
Malignant melanoma is a devastating disease with significant resistance to current therapies
(36). Recently, anti-angiogenic inhibitors have shown promising therapeutic potentials in
melanoma (7, 37). A common target for anti-angiogenic therapy is VEGF. Several VEGF
inhibitors have been pursued clinically and some of them have been approved by FDA (38).
However, relapse was frequently observed in VEGF inhibitor-treated patients (6, 7), partly
attributable to incomplete inhibition of VEGF activity. Most of the VEGF inhibitors block
the downstream effects of VEGF, after its secretion and release from cells, either by
neutralizing diffusible VEGF or inhibiting the signaling pathway it stimulates. Since the
supply of VEGF is not affected, continuous administration of inhibitors is required to
sequester its activity and frequently some VEGF escapes the inhibition, by its retention in
extracellular matrix (ECM), for example (39). This problem may be alleviated by reducing
production and/or secretion of bioactive VEGF at source, thus increasing the efficacy of
anti-angiogenic effects of VEGF inhibitors.
G protein-coupled receptors constitute over 40% of drug targets for treatment of human
diseases, but they have not been the main targets for cancer control, mostly due to a lack of
understanding of their roles in cancer progression. The involvement of GPCRs on VEGF
production in cancer cells has been reported and shown to involve the p38/MAPK pathway
(40). We report here that an adhesion GPCR, GPR56, regulates VEGF production and
melanoma angiogenesis through a signaling pathway mediated by protein kinase Cα (Figure
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7). We also present evidence that the two fragments of GPR56, generated by cleavage upon
receptor maturation, could play distinct roles in their regulation of melanoma angiogenesis
and progression. While expression of its C-terminal fragment (GPRC) induced VEGF
secretion in MC-1 cells, expression of the full-length receptor inhibited it. Most signaling
receptors exhibit a certain degree of basal/constitutive activities (41). We postulate that the
“free” GPRC might be in such a state and its over-expression led to stimulated VEGF
production and melanoma progression (Figure 7). GPRN and ΔSTP-GPRN might inhibit
and activate this basal activity of GPRC, respectively, resulting in opposing effects on
melanoma progression. Consistent with this notion, our data showed that purified FcGPRN
protein was sufficient to inhibit VEGF production from MC-1(GPRC) cells (Figure 4D).
ΔSTP-GPR56 promoted VEGF production in multiple melanoma cell lines (Figure 4C),
suggesting that the activation mechanisms and resulted functions of GPR56 may be shared
among malignant melanomas. Interestingly, alternatively spliced isoforms of GPR56 were
reported recently and two of them encode proteins similar to ΔSTP-GPR56 (42). Although
the ΔSTP isoforms may function differently in different cell types - they were shown to
inhibit the VEGF promoter in HEK293 cells rather than enhancing VEGF production (42),
their very existence suggests that perturbing GPR56, by inhibiting its endogenous ΔSTP or
activated isoforms, could be used as a strategy to effectively curb angiogenesis and
melanoma progression, especially when combined with other VEGF inhibitors. Normal
adult tissues tend to express low levels of GPR56 relative to cancerous tissues (43), and
Gpr56−/− mice or human patients carrying mutations in the GPR56 gene are viable and
grossly healthy, despite defects in brain development (18, 44). Therefore, perturbing GPR56
and its mediated signaling pathway may have few detrimental side effects on cancer patients
as long as they do not penetrate the blood-brain barrier.
Whether GPR56 functions similarly in endogenous melanoma progression as in xenografts
is yet to be determined. We reported previously that melanoma development in the Ink4a/
Arf−/− tyr-HRAS mice did not alter significantly in the absence of GPR56 (43). Perhaps
GPR56 plays dual roles in endogenous melanoma progression, as in xenografts, and its
complete absence abolishes both and leads to an outcome similar to that in wild-type mice.
Alternatively, GPR56 expressed on stromal cells also affect tumor development in
endogenous melanomas, which was not assessed in the xenograft model.
The signaling pathways mediated by GPR56, or adhesion GPCRs in general, are poorly
understood, despite their increasingly recognized importance in development and diseases
(17–22). The results from our study serve as a platform for further investigations in this area.
For example, it is not clear whether the inhibition or activation of GPRC imposed by GPRN
or ΔSTP-GPRN might involve other interacting proteins. We previously reported that TG2
binds to GPRN (25). However, knockdown of TG2 in MC-1(GPR56) cells by RNAi did not
lead to an increase of VEGF production as observed in MC-1(ΔSTP-GPR56) cells,
suggesting that the roles of TG2 in GPR56-mediated signaling are not straightforward. It is
possible that other factor(s) binds to the STP segment in GPRN and mediates the
inactivation of GPRC. The expression or stability of this factor(s) may thus determine the
activity of GPR56 in cancer cells. Finally, GPR56 was reported to associate with Gαq (45),
consistent with its regulation of PKC activation. Whether this is the case also needs to be
investigated.
The apparent separate functions of GPRN and GPRC indicated by our results support the
recent proposal that the two subunits of adhesion GPCRs might function as distinct entities
(46). It was reported that the two fragments of latrophilin, another adhesion GPCR, could
associate with and potentially signal through fragments from other adhesion GPCRs. The
GPCR proteolytic site (GPS) is conserved in all adhesion GPCRs and those tested were
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shown to be cleaved into two fragments (17). Their potential to play distinct functions
promises a great complexity of regulation by the adhesion GPCRs in a range of biological
processes, including cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. GPR56 inhibits angiogenesis in melanomas
A. Expression of GPR56 resulted in reduction in angiogenesis. Tumor sections from
melanoma cells expressing wild-type GPR56 or vector control were stained with anti-GPRC
antibody (red) and anti-PECAM antibody (green).
B. Quantification of blood vessel density in GPR56-expressing tumors and vector control.
C. Quantifications of blood vessel density in areas of the same GPR56-expressing tumors.
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Figure 2. Ectopic expression of GPRC fragment induces tumor angiogenesis and growth in
MC-1 cells
A. Expression of GPRC in MC-1 cells significantly enhanced tumor growth.
B. Expression of GPRC induced tumor angiogenesis. Tumor sections from MC-1(EV) and
MC-1(GPRC) cells were stained with the anti-PECAM antibody (green) and the anti-GPRC
(red).
C. Blood vessel densities were significantly higher in tumors from the MC-1(GPRC) cells
than those from the MC-1(EV) cells. **: p < 0.001, Student’s t-test.
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Figure 3. Deletion of the STP segment in GPR56 led to significantly enhanced tumor growth and
angiogenesis
A. Western blot analyses of the expression of ΔSTP-GPR56 in MC-1 cells.
B. Expression of ΔSTP-GPR56 led to enhanced tumor growth. *: p < 0.05; **: p < 0.01;
***: p < 0.001. Student’s t-test.
C. Expression of ΔSTP-GPR56 led to enhanced tumor angiogenesis. Tumor sections were
stained with the anti-PECAM antibody (green) and the anti-GPRC antibody (red).
D. Blood vessel density on sections stained with anti-PECAM antibody was quantified as
described in the legend for Figure 2. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Student’s t-
test.
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Figure 4.
GPR56 regulates melanoma progression by inhibiting VEGF production through the STP
segment.
A. Expression of GPR56 significantly inhibited production of VEGF in the media of MC-1
cells, but expression of ΔSTP-GPR56 enhanced it.
B. Expression of GPRC in MC-1 cells significantly increased production of VEGF.
C. Expression of ΔSTP-GPR56 induced VEGF production in multiple melanoma cell lines.
D. FcGPRN-1 protein inhibited VEGF production from MC-1(GPRC) cells. FcLA protein
was used as a control.
E. VEGF mRNA was knocked down by shRNAs in MC-1(ΔSTP-GPR56) cells.
F. Knocking down of VEGF in MC-1(ΔSTP-GPR56) cells led to a reduction in tumor
growth.
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Figure 5. GPR56 and ΔSTP-GPR56 regulate VEGF secretion through PKCα
A: Activation of PKC by PMA rescued the inhibition of VEGF secretion by GPR56.
B. Inhibition of PKC activities led to a reduction in VEGF secretion from MC-1 cells.
C. Inhibition of PKC activities led to a reduction of VEGF secretion from MC-1(ΔSTP-
GPR56) cells. Serum starved MC-1(ΔSTP-GPR56) cells were incubated with PKC
inhibitors for 4 hours before the media were collected for ELISA analyses.
D. PKCα was reduced in the particular fractions from MC-1(GPR) cells, but increased in
those of MC-1(ΔSTP-GPR) and MC-1(GPRC) cells, relative to MC-1(EV) cells. LRP6 was
used as a loading control.
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E. Expression of dominant negative (DN) PKCα in MC-1(ΔSTP-GPR) or MC-1(GPRC)
cells led to reduced VEGF production in the medium.
F. Expression of DN-PKCα inhibited PMA-induced production of VEGF in MC-1(GPR56)
cells.
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Figure 6. The expression levels of GPR56 are inversely correlated with melanoma progression
A, B. Immunohistochemical analyses on sections from wild-type or Gpr56−/− testes (A), or
tumors from MC-1 cells that express human GPR56 (B). The anti-GPRN antibody
specifically recognized GPR56 on these sections.
C. Immunohistochemical analyses on melanoma tissue microarrays using the anti-GPRN
antibody.
D. Expression intensity scores of GPR56 on melanoma tissue microarrays. **: p < 0.001;
***: p < 0.0001.
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Figure 7. Model of GPR56 function in VEGF production by melanoma cells
We hypothesize that the free GPRC fragment of GPR56 represents a basal/constitutive “on”
state to induce the activation of PKCα, VEGF production, angiogenesis, and melanoma
progression. The binding of full-length GPRN switches GPRC to an “off” state and inhibits
those processes. The binding of ΔSTP-GPRN, however, activates it and promotes melanoma
progression.
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